|Bid||134.06 x 800|
|Ask||135.05 x 1200|
|Day's Range||127.75 - 135.23|
|52 Week Range||53.40 - 140.89|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||734.02|
|Earnings Date||Feb 25, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.00|
A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech.
Novocure will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020.
Shares of Novocure (NASDAQ: NVCR) were sinking 9.2% as of 3:30 p.m. on Tuesday. The oncology therapy company didn't announce any news, so why did the stock fall on a day when the overall market soared? The most likely reason is that some investors decided to lock in profits after Novocure's year-to-date gain of nearly 60% as of the market close on Monday.